EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Antibody-drug conjugates in cancer therapy: current advances and prospects for breakthroughs

Dan Wu, Kaixuan Yang, Runjia He, Rutie Yin, Lin Shui

Frontiers in Cell and Developmental Biology · 08.10.2025 · 13

DOI: 10.3389/fcell.2025.1669592 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 08.10.2025. Verfasst von Dan Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 243 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-drug conjugates (ADCs), often referred to as “intelligent biological missiles,” have garnered significant attention in the rapidly evolving landscape of cancer therapy. ADCs represent a sophisticated approach by integrating monoclonal antibodies (mAbs), which are particular targeting tumor antigens, with cytotoxic payloads, which deliver lethal effects. Compared with the combination of chemotherapy and mAbs, ADCs precisely deliver highly potent cytotoxins directly to tumor cells while minimizing damage to healthy tissues. However, limitations such as significant adverse effects, suboptimal therapeutic efficacy, and drug resistance require carefully evaluation and further optimization. Further studies are necessary to explore the next-generation of ADCs, such as the combination of ADCs with other anti-tumor strategies, bispecific ADCs, dual-payload ADCs and radionuclide drug conjugates (RDCs). This review provides a comprehensive overview of recent developments in oncology treatment, focusing on the historical evolution, structural design, clinical advancements, and mechanisms of action of approved ADCs. Each structural element, including the target antigen, mAb, linker system, and cytotoxic payload, as well as advancements in payload conjugation technology, plays a critical role in the development of ADCs. Through ongoing refinement and innovation, it is anticipated that next-generation ADCs with enhanced therapeutic benefits for patient populations can be realized.

Schlagwörter

Stichwörter der Autor:innen

antibody drug conjugate (ADC)antitumor treatmentdrug approvallinkerpayload

Autor:innen und Institutionen

  • Cancer Center, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Chengdu, Sichuan, China.
  • School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, China.
  • Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.

Zitieren

APA

Wu, D., Yang, K., He, R., Yin, R., & Shui, L. (2025). Antibody-drug conjugates in cancer therapy: current advances and prospects for breakthroughs. Frontiers in Cell and Developmental Biology, 13. https://doi.org/10.3389/fcell.2025.1669592

Vancouver

Wu D, Yang K, He R, Yin R, Shui L. Antibody-drug conjugates in cancer therapy: current advances and prospects for breakthroughs. Frontiers in Cell and Developmental Biology. 2025;13. doi:10.3389/fcell.2025.1669592

BibTeX
@article{Wu2025,
  author = {Wu, Dan and Yang, Kaixuan and He, Runjia and Yin, Rutie and Shui, Lin},
  title = {Antibody-drug conjugates in cancer therapy: current advances and prospects for breakthroughs},
  journal = {Frontiers in Cell and Developmental Biology},
  year = {2025},
  volume = {13},
  doi = {10.3389/fcell.2025.1669592}
}
Kostenlos starten →